Effect of the COVID-19 pandemic on patients with inherited neuromuscular disorders

ABSTRACT

Background The COVID-19 pandemic has brought substantial challenges for current practices in treating hereditary neuromuscular disorders (hNMDs). However, this infection has not been the only concern for these patients. Social distancing has compromised multidisciplinary assistance and physical activity, and has brought about several mental health issues. We presented a follow-up on 363 patients with hNMDs at a Brazilian tertiary center during the peak of the COVID-19 pandemic. Objective We aimed to show the frequency and severity of SARS-CoV-2 infection among hNMD patients and to demonstrate the effects of the pandemic on life habits, disease progression and multidisciplinary supportive care status. Methods Three hundred and sixty-three patients (58% male and 42% female) were followed for three months through three teleconsultations during the peak of the COVID-19 pandemic in Brazil. Results There were decreases in the numbers of patients who underwent physical, respiratory and speech therapies. For several patients, their appetite (33%) and sleep habits (25%) changed. Physical exercises and therapies were interrupted for most of the patients. They reported new onset/worsening of fatigue (17%), pain (17%), contractions (14%) and scoliosis (7%). Irritability and sleep, weight and appetite changes, and especially diminished appetite and weight loss, were more frequent in the group that reported disease worsening. There was a low COVID-19 contamination rate (0.8%), and all infected patients had a mild presentation. Conclusion The isolation by itself was protective from a COVID-19 infection perspective. However, this isolation might also trigger a complex scenario with life habit changes that are associated with an unfavorable course for the NMD.

RESUMO

Antecedentes: A Pandemia por COVID-19 tem trazido desafios subtanciais para a prática clínica no tratamento das doenças neuromusculares hereditárias (DNMh). A infecção não tem sido a única preocupação para os pacientes. O distanciamento social tem comprometido a assistência multidisciplinar, atividade física e tem trazido problemas mentais em decorrência do próprio isolamento. Nós apresentamos aqui um seguimento de 363 pacientes com DNMh de um centro terciário Brasileiro durante o pico da Pandemia de Covid-19. Objetivos: Mostrar a frequência e gravidade da infecção por Sars-Cov-2 em pacientes com DNMh e demonstrar os efeitos da pandemia nos hábitos de vida, na progressão da doença e no cuidado multidisciplinary. Métodos Trezentos e sessenta e três pacientes (58% homens and 42% mulheres) foram acompanhados por 3 meses através de 3 teleconsultas durante o pico da Pandemia de Covid-19 no Brasil. Resultados Houve um decréscimo no número de pacientes que faziam terapia física, respiratória e fonoaudiológica. Em muitos pacientes, o apetite (33%) e hábitos do sono (25%) se alteraram. Exercícios físicos e terapias foram interrompidas pela maioria dos pacientes. Physical exercises and therapies were interrupted for most of the patients. Eles relataram piora ou aparecimento de fadiga (17%), dor (17%), retrações (14%), e escoliose (7%). Irritabilidade, mudanças no sono, peso e apetite, sendo principalmente diminuição do apetite e peso foram mais frequentemente encontrados em pacientes que apresentaram piora clinica da doença. Houve uma baixa taxa de contaminação por Covid-19 (0.8%), e todos os pacientes infectado apresentaram quadro clinico leve. Conclusão O isolamento por si só se mostrou protetor na perspectiva de infecção por Covid-19, mas pode desencadear um cenário complexo com mudanças nos hábitos de vida e curso desfavorável da doença de base.

Keywords:

Neuromuscular Diseases - COVID-19 - Social Isolation - Consequence Analysis

Palavras-chave:

Doenças Neuromusculares - COVID-19 - Isolamento Social - Análise de Consequências

Authors’ contributions:

All authors contributed to the study conception, design and data collection. The data analysis and the first draft of the manuscript was done by the correspondence author and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript

Publication History

Received: 06 August 2021

Accepted: 31 August 2021

Article published online:
06 February 2023

• REFERENCES

• 1 Guidon AC, Amato AA. COVID-19 and neuromuscular disorders. Neurology 2020; 94 (22) 959-969 https://doi.org/10.1212/WNL.20210166202101669566
• 2 Laventhal NT, Graham RJ, Rasmussen SA, Urion DK, Kang PB. Ethical decision-making for children with neuromuscular disorders in the COVID-19 crisis. Neurology 2020; 95 (06) 260-265 https://doi.org/10.1212/WNL.20210166202101669936
• 3 Grossman SN, Han SC, Balcer LJ, Kurzweil A, Weinberg H, Galetta SL. et al. Rapid implementation of virtual neurology in response to the COVID-19 pandemic. Neurology 2020; 94 (24) 1077-1087 https://doi.org/10.1212/WNL.20210166202101669677
• 4 Veerapandiyan A, Connolly AM, Finkel RS, Arya K, Mathews KD, Smith EC. et al. Spinal muscular atrophy care in the COVID-19 pandemic era. Muscle Nerve 2020; 62 (01) 46-49 https://doi.org/10.1002/mus.26903
• 5 Solé G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P. et al. Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris) 2020; 176 (06) 507-515 https://doi.org/10.1016/j.neurol.2020.04.004
• 6 Studart-Neto A, Guedes BF, Tuma RLE, Camelo Filho AE, Kubota GT, Iepsen BD. et al. Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital. Arq Neuropsiquiatr 2020; 78 (08) 494-500 https://doi.org/10.1590/0004-282x20200089
• 7 Dowling JJ, Gonorazky HD, Cohn RD, Campbell C. Treating pediatric neuromuscular disorders: the future is now. Am J Med Genet A 2018; 176 (04) 804-841 https://doi.org/10.1002/ajmg.a.38418
• 8 Korinthenberg R. Neuromuscular disorders in children and adolescents. Neuropediatrics 2017; 48 (04) 209-210 https://doi.org/10.1055/s-0037-1603980
• 9 Camelo-Filho AE, Silva AMS, Estephan EP, Zambon AA, Mendonça RH, Souza PVS. et al. Myasthenia Gravis and COVID-19: clinical characteristics and outcomes. Front Neurol 2020; 11: 1053 https://doi.org/10.3389/fneur.2020.01053
• 10 Dalakas MC. Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing. Neurol Neuroimmunol Neuroinflamm 2020; 7 (05) e781 https://doi.org/10.1212/NXI.20210166202101660781
• 11 Bellino S, Punzo O, Rota MC, Del Manso M, Urdiales AM, Andrianou X. et al. COVID-19 disease severity risk factors for pediatric patients in Italy. Pediatrics 2020; 146 (04) e2020009399 https://doi.org/10.1542/peds.2020-009399
• 12 Di Stefano V, Battaglia G, Giustino V, Gagliardo A, D'Aleo M, Giannini O. et al. Significant reduction of physical activity in patients with neuromuscular disease during COVID-19 pandemic: the long-term consequences of quarantine. J Neurol 2021; 268 (01) 20-26 https://doi.org/10.1007/s00415-020-10064-6
• 13 Handberg C, Werlauff U, Højberg A-L, Knudsen LF. Impact of the COVID-19 pandemic on biopsychosocial health and quality of life among Danish children and adults with neuromuscular diseases (NMD)-Patient reported outcomes from a national survey. PLoS One 2021; 16 (06) e0253715 https://doi.org/10.1371/journal.pone.0253715
• 14 Pfefferbaum B, North CS. Mental health and the Covid-19 Pandemic. N Engl J Med 2020; 383 (06) 510-512 https://doi.org/10.1056/NEJMp2008017